RAPGEF5 and dengue disease: In recent years, several studies have been published on anti-GFR tyrosine kinase inhibitors (TKIs) in dengue, such as dasatinib [114], sunitinib/erlotinib [115], gefitinib [116], brivanib [117], afatinib-derivative (L3) [118], sunitinib/anti-TNF antibody [119], and TGF-β receptor 1 and 2 inhibitors (GW788388) [93].